IGI Logo

Tier-II Outperformance Widens; Revenue Conversion Remains the Key Constraint

Q1FY27 was broadly balanced, with improving demand indicators offset by muted revenue growth and near-term margin pressures. Deal momentum remained healthy across the sector, led by large transformation, vendor consolidation and AI-led programmes. Growth divergence widened further with Tier-I revenue growth at ~0.2% QoQ, led by TECHM (+2.2%) and INFY (+0.8%), while TCS was flat and HCLT (-0.6%) and WPRO (-2.4%) declined. The muted performance reflects continued discretionary weakness, delayed deal ramp-ups and softness in select verticals, despite healthier demand in BFSI and Healthcare. Tier-II remained the clear outperformer at ~6% QoQ, led by PSYS (+21.1%), COFORGE (+3.8%) and MPHL (+3.4%), supported by stronger execution, large-account ramp-ups and AI-led transformation. Importantly, the divergence is less a function of demand strength alone and increasingly reflects differences in deal conversion and execution velocity, favouring agile Tier-II players in the near term.

Healthy Bookings Contrast with Muted Revenue Conversion

Deal momentum remained healthy, with strong bookings contrasting with subdued revenue conversion. Tier-I continued to secure large transformation deals, led by TCS, while INFY and HCLT maintained healthy pipelines despite elongated decision cycles. Tier-II remained stronger, led by PSYS’ record USD 1.15 Bn TCV and COFORGE’s robust executable order book. The key constraint is increasingly conversion rather than demand, with AI-led transformation and vendor consolidation supporting pipelines, but phased ramps delaying revenue recognition. Hence, FY27 visibility is improving, although deal conversion remains the key swing factor.

Margin Performance Mixed; Productivity Gains Offset Near-Term Cost Pressures

Margins were mixed in Q1, with wage hikes, deal transition costs and continued investments in AI weighing on several players, although utilisation and productivity provided partial offsets. Tier-I was relatively resilient, led by TECHM’s ~60 bps QoQ expansion to 14.4% on volume growth, Project Fortius savings and SG&A discipline, while INFY also improved margin. Tier-II was more uneven, with PSYS and MPHL facing pressure from lower utilisation and deal ramp-up cost, while HAPPSTMN expanded margin on higher utilisation and AI-led productivity. We believe AI investments, proactive hiring and wage hike will cap near-term margin expansion, although productivity gains, utilisation recovery and pricing discipline should provide offsets. Execution and faster conversion of deal pipelines into revenue will remain key differentiators.

Valuation: Re-rating Now Hinges on Earnings Delivery; Stay Selective

Indian IT valuations have rebounded post Q1FY27, with the Nifty IT Index up ~20% from its July 2026 lows, although still negative on YTD basis. The recovery reflects improving sentiment, healthy deal pipelines and better H2FY27 demand commentary; however, risk-reward has now moved to a more balanced zone, making further upside momentum increasingly dependent on execution and earnings delivery. AI monetisation remains the key structural debate, with early adoption creating near-term deflationary pressure on effort-based revenues before meaningful AI-led scale-up. Within Tier I, we favour TCS and TechM for stronger margin resilience and deal conversion, while COFORGE and PSYS remains our preferred companies in the mid-cap, given superior growth visibility, sustained deal momentum and consistent execution. We expect the sector’s re-rating to become increasingly stock-specific and execution-led, rather than broad-based.

For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer

SEBI Registration no.: INZ 000160131